CSL Behring

News

Sanofi says drug for rare disease AATD tops standard care

After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.

News

NICE finalises support for CSL's HAE therapy Andembry

CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE.

News

CSL will slash headcount and hive off vaccine business

Facing declines in flu vaccination rates in the US, CSL will spin out its vaccine unit as part of a wider restructuring that will claim 3,000 jobs.

News

Germany will reimburse haemophilia gene therapy Hemgenix

Germany has agreed to reimburse CSL Behring's haemophilia B gene therapy Hemgenix with a 'unique' outcomes-based payment model.

News

EU approves CSL's once-monthly HAE drug Andembry

The EU has approved CSL's once-monthly Andembry for hereditary angioedema, challenging therapies from Takeda and Biocryst.

News

England, Denmark back CSL’s haemophilia B gene therapy

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark.

Sanofi says drug for rare disease AATD tops standard care

NICE finalises support for CSL's HAE therapy Andembry

CSL will slash headcount and hive off vaccine business

Germany will reimburse haemophilia gene therapy Hemgenix

EU approves CSL's once-monthly HAE drug Andembry

England, Denmark back CSL’s haemophilia B gene therapy

Ipsen charts $1.75bn course for Kartos acquisition

Discover a new era of healthcare panel engagement: Grounded ...

CSL Behring

Editor's Picks